Bengaluru, February 28, 2025: On the occasion of Rare Disease Day, Strand Life Sciences, a Reliance Industries subsidiary and leading genomics company, today launched the StrandOmics Portal to improve diagnosis of rare diseases.
This new online portal gives clinicians quick and easy access to information on genetic variants, giving them a comprehensive view for each case. This means faster and more accurate diagnosis for patients.
In addition to the portal, Strand Life Sciences will offer rare disease genetic testing at a reduced cost for patients from economically disadvantaged backgrounds, making these crucial tests more accessible.
The StrandOmics Portal helps doctors by:
Providing clear and quick genetic insights for better diagnosis
Allowing doctors to independently review a broader set of genetic variants
Improving prenatal diagnosis through better collaboration between specialists
Dr. Ramesh Hariharan, CEO & Co-Founder of Strand Life Sciences, said, “We are dedicated to improving genetic diagnostics and making it available to everyone. We will continue to innovate and invest in tools like the StrandOmics Portal to empower doctors in their fight against rare diseases.”
About Strand Life Sciences:
Strand Life Sciences, a subsidiary of Reliance Industries Limited, is a genomics-based research and diagnostics company that combines a long track record in bioinformatics with cutting-edge laboratory assays and a vast hospital partner network to drive newer generations of patient care. Strand’s customers include global medical instruments, diagnostic, and pharmaceutical companies. Strand is also a pioneer of genomic testing in India, and its long global bioinformatics track record makes it the most trusted company for genomic diagnostics in the areas of oncology, rare diseases, women’s health, and infectious diseases. Additionally, Strand is actively expanding into consumer genomics, empowering individuals with personalized insights into their genetic makeup.
